natgillin/translations-raw huggingface dataset:
In responding patients, the alternative strategies for continued treatment are: 
Pri bolnikih, ki so se odzvali na zdravilo, so druge možnosti nadaljnjega zdravljenja naslednje:
Placebo patients received methotrexate while infliximab patients received both infliximab and methotrexate. 
Bolniki iz placebo skupine so prejemali metotreksat, medtem ko so bolniki iz infliksimabove skupine prejemali tako infliksimab kot metotreksat.
At 38 weeks, 9 of 101 patients treated with Remicade (2 at 5 mg/kg and 7 at 10 mg/kg) died compared to one death among the 49 patients on placebo. 
Po 38 tednih je umrlo 9 od 101 bolnikov, zdravljenih z zdravilom Remicade (2 z odmerkom 5 mg/kg in 7 z odmerkom 10 mg/kg), v primerjavi z eno smrtjo pri 49 bolnikih, ki so prejemali placebo.
AZA was given at a dose of 2.5 mg/kg daily. 
AZA so bolniki prejemali v odmerku 2,5 mg/kg na dan.
14 weeks 
14 tednov
• Infection of the skin due to a fungus 
• okužba kože zaradi glivic
In the 6 mg/kg group, 2 out of 57 patients had a serious infusion reaction, one of whom had a possible anaphylactic reaction (see section 4.4). 
V skupini, ki je zdravilo prejemala v odmerku 6 mg/kg, pa sta imela 2 od 57-tih bolnikov resno z infuzijo povezano reakcijo in eden od njiju je morda imel anafilaktično reakcijo (glejte poglavje 4.4).
• This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25 °C for a single period of up to six months, but not beyond the original expiry date. 
• To zdravilo se lahko shranjuje tudi v originalni škatli izven hladilnika do največ 25 °C za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
• Some patients treated with infliximab have developed certain kinds of skin cancer. 
• Pri nekaterih bolnikih, zdravljenih z infliksimabom, so se pojavile določene vrste kožnega raka.
Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects). 
Analiza se nanaša na preiskovance, ki so imeli psoriazo nohtov na začetku študije (81,8 % preiskovancev).
• Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis). 
• imunske bolezni, ki lahko prizadenejo pljuča, kožo in bezgavke (na primer sarkoidoza)
In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients receiving Remicade without progression to severe hepatic injury. 
V kliničnih preskušanjih so opažali blago ali zmerno zvišanje vrednosti ALT in AST pri bolnikih, ki so prejemali zdravilo Remicade, brez napredovanja motnje do hude jetrne poškodbe.
Cases of tuberculosis, sometimes fatal, including miliary tuberculosis and tuberculosis with extra-pulmonary location have been reported (see section 4.4). 
Poročali so tudi o primerih tuberkuloze, včasih celo s smrtnim izidom, vključno z miliarno tuberkulozo in tuberkulozo izven pljuč (glejte poglavje 4.4).
SPIRIT evaluated the efficacy of infliximab induction therapy in 249 patients with plaque psoriasis that had previously received PUVA or systemic therapy. 
V študiji SPIRIT so ocenjevali učinkovitost uvodne terapije z infliksimabom pri 249 bolnikih s psoriazo s plaki, ki so pred tem prejemali PUVA ali sistemsko terapijo.
• Reactions at the injection site such as pain, swelling, redness or itching 
• reakcije na mestu injiciranja, na primer bolečina, otekanje, pordelost ali srbenje
In clinical studies, delayed hypersensitivity reactions have been uncommon and have occurred after Remicade-free intervals of less than 1 year (see sections 4.4 and 4.8). 
V kliničnih študijah so bile pozne preobčutljivostne reakcije občasne in so se pojavile po premoru brez prejemanja zdravila manj kot 1 leto (glejte poglavji 4.4 in 4.8).
In ACT 1 and ACT 2, infliximab improved quality of life, confirmed by statistically significant improvement in both a disease specific measure, IBDQ, and by improvement in the generic 36-item short form survey SF-36. 
V študijah ACT 1 in ACT 2 je infliksimab tudi izboljšal kakovost življenja bolnikov, kar je bilo potrjeno s statistično značilnim izboljšanjem rezultata vprašalnika za oceno vnetnih bolezni črevesja IBDQ, ki je specifičen za to bolezen, in z izboljšanjem rezultatov generične kratke ankete SF-36 s 36 postavkami.
• Merkel cell carcinoma (a type of skin cancer) 
• karcinom Merklovih celic (vrsta kožnega raka)
In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, antituberculosis therapy should be considered before the initiation of Remicade. 
Pri bolnikih, ki imajo več dejavnikov tveganja oziroma pomembne dejavnike tveganja za tuberkulozo in pri katerih je bil test na latentno tuberkulozo negativen, premislite, ali bi bilo treba pri njih pred uvedbo zdravila Remicade najprej zdraviti tuberkulozo.
• Infection due to a live vaccine because of a weakened immune system. 
• okužba zaradi živega cepiva zaradi oslabljenega imunskega sistema
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Remicade and is positive for antibodies against double-stranded DNA, further treatment with Remicade must not be given (see section 4.8). 
Če se po zdravljenju z zdravilom Remicade pri bolniku pojavijo simptomi, ki kažejo na lupusu podoben sindrom, in je bolnik pozitiven na protitelesa proti dvojnoverižni DNA, ne sme več prejeti tega zdravila (glejte poglavje 4.8).
At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders. 
Čez 102 tedna se je z infliksimabom še vedno zdravilo 80 preiskovancev in od tega jih je imelo kar 71 (89 %) odziv ASAS 20.
• Some patients receiving Remicade have developed serious liver problems. 
• Pri nekaterih bolnikih, ki prejemajo zdravilo Remicade, so se pojavile resne težave z jetri.
Long-term studies have not been performed to evaluate the carcinogenic potential of infliximab. 
Dolgoročne študije za ovrednotenje kancerogenosti infliksimaba niso bile izvedene.
• Tell your doctor before you are given Remicade if you are a carrier of hepatitis B or have ever had it. 
• Preden prejmete zdravilo Remicade, povejte zdravniku, če ste prenašalec hepatitisa B ali če ste ga imeli kdaj v preteklosti.
• Tell your doctor if you think you might be at risk of contracting hepatitis B. 
• Povejte zdravniku, če mislite, da pri vas obstaja možnost, da bi se okužili s hepatitisom B.
Higher degrees of clinical response (ACR50 and ACR70) were observed in all infliximab groups at 30 and 54 weeks compared with methotrexate alone. 
Izrazitejši klinični odziv (ACR 50 in ACR 70) so v 30. in 54. tednu opažali v vseh skupinah, ki so prejemale infliksimab, v primerjavi z bolniki, ki so prejemali le metotreksat.
Week 54 Clinical Response 
54. teden Klinični odziv
control = All patients had active RA despite treatment with stable methotrexate doses for 6 months prior to enrolment and were to remain on stable doses throughout the study. 
Kontrolna skupina: Vsi bolniki so imeli aktivni revmatoidni artritis kljub zdravljenju s stalnimi odmerki metotreksata že 6 mesecev pred vključitvijo v študijo; te odmerke so prejemali še naprej ves čas študije.
Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology. 
Infliksimab je himerno človeško-glodalsko monoklonsko protitelo IgG1, pridobljeno iz celic glodalskega hibridoma s tehnologijo rekombinantne DNK.
Ask your doctor to record the type and date of last screening(s) for tuberculosis (TB) below: Test 
Zdravnik naj zabeleži tip in datum zadnjega presejalnega(ih) testa(ov) za tuberkulozo (TBC):
All patients were required to be on a stable dose of 6-MP, AZA or MTX (35% were also receiving corticosteroids at baseline). 
Vsi bolniki so morali prejemati stalen odmerek 6-MP, AZA ali MTX (35 % jih je na začetku prejemalo tudi kortikosteroide).
• Inflammation of the lining of the brain (meningitis) 
• vnetje možganskih ovojnic (meningitis)
Lung disease or heavy smoking 
Pljučna bolezen ali bolniki, ki veliko kadijo
The combination of Remicade and abatacept is not recommended. 
Kombiniranje zdravila Remicade in abatacepta torej ni priporočljivo.
Infliximab-treated patients demonstrated significant improvement in physical function as assessed by HAQ. 
Pri bolnikih, zdravljenih z infliksimabom, so ugotovili bistveno izboljšanje funkcije sklepov, kar so ocenjevali z vprašalnikom HAQ.
• Circulation problems such as low or high blood pressure 
• težave s krvnim obtokom, na primer nizek ali visok krvni tlak
Invasive fungal infections 
Invazivne glivične okužbe
Remicade has been studied only in combination with conventional immunosuppressive therapy. 
Zdravilo so preučevali le v kombinaciji z običajno imunosupresivno terapijo.
• The active substance is infliximab. 
• Učinkovina je infliksimab.
Remicade treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis or psoriasis. 
Zdravljenje z zdravilom Remicade mora uvesti in nadzorovati kvalificiran zdravnik, ki je izkušen v diagnostiki in zdravljenju revmatoidnega artritisa, vnetnih bolezni črevesa, ankilozirajočega spondilitisa, psoriatičnega artritisa ali psoriaze.
Due to methodological limitations, a negative assay did not exclude the presence of antibodies to infliximab. 
Zaradi pomanjkljivosti uporabljene metode pa negativen izvid ni izključil možnosti za prisotnost protiteles proti infliksimabu.
Significant improvements in health-related quality of life were also demonstrated as measured by the physical and mental component summary scores of the SF-36 in IMPACT 2. 
Ugotovili so tudi bistveno izboljšanje kakovosti življenja v zvezi z zdravjem, kar so merili na podlagi delnih ocen, to je seštevkov za telesne in duševne komponente SF-36 v študiji IMPACT 2.
• Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur followed by infusions of 5 mg/kg every 8 weeks (see ‘Re-administration' below and section 4.4). 
• Ponovna uporaba zdravila: Infuzija v odmerku 5 mg/kg, če se ponovijo znaki in simptomi bolezni, čemur naj sledijo infuzije v odmerku 5 mg/kg na vsakih 8 tednov (glejte poglavje “Ponovna uporaba zdravila” spodaj in poglavje 4.4).
The volume of distribution at steady state (median Vd of 3.0 to 4.1 litres) was not dependent on the administered dose and indicated that infliximab is predominantly distributed within the vascular compartment. 
(mediana Vd od 3,0 do 4,1 litra) ni bil odvisen od danega odmerka, kar pomeni, da se infliksimab razporedi pretežno po žilnem razdelku.
Heart problems 
Težave s srcem
As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. 
Če ste prejeli prevelik odmerek zdravila Remicade Ker boste zdravilo prejeli od zdravnika ali medicinske sestre, je zelo malo verjetno, da ga boste prejeli preveč.
Structural joint damage (erosions and joint space narrowing) in both hands and feet was measured by the change from baseline in the total van der Heijde-modified Sharp score (0-440). 
Strukturne okvare sklepov (erozije in zožitev sklepne špranje) tako na rokah kot na stopalih so merili na podlagi spremembe skupnega rezultata po metodi van der Heijde, modificirani po Sharpu (0 - 440) glede na začetne vrednosti.
Caution should also be exercised in patients with psoriasis and a medical history of extensive immunosuppressant therapy or prolonged PUVA treatment. 
Previdnost je potrebna tudi pri bolnikih s psoriazo in obsežno imunosupresivno terapijo ali daljšim zdravljenjem s PUVA v anamnezi.
In Crohn's disease, experience with re-administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking. 
Pri Crohnovi bolezni je malo izkušenj s ponovnim dajanjem zdravila po ponovitvi znakov in simptomov bolezni, primerjalnih podatkov o razmerju med koristmi in tveganji drugih možnosti nadaljnjega zdravljenja pa ni.
Care should be taken and patients should continue to be monitored when switching from one biologic to another, since overlapping biological activity may further increase the risk for adverse reactions, including infection. 
Prehod na zdravljenje z drugim biološkim zdravilom tipa DMARD Pri prehodu z enega biološkega zdravila na drugega je potrebna previdnost, bolnike pa je treba še naprej spremljati, ker se zaradi prekrivanja biološke učinkovitosti lahko še poveča tveganje za neželene učinke, vključno z okužbami.
• Low blood counts, including a severely decreased number of white blood cells 
• nizko število krvnih celic, vključno z močnim znižanjem števila belih kvnih celic
Because of the nature of the adverse reactions seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF-blocking agents. 
Glede na vrsto neželenih učinkov, ki so jih opažali pri kombinirani terapiji z etanerceptom in anakinro, lahko podobni toksični učinki nastopijo tudi kot posledica kombiniranja anakinre in drugih zaviralcev TNF.
• Blood problems such as anaemia or low white blood cell count 
• težave s krvjo kot na primer anemija ali nizko število belih krvnih celic
In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of Remicade (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1 hour. 
Skrajšane infuzije pri indikacijah za odrasle bolnike Pri skrbno izbranih odraslih bolnikih, ki so dobro prenesli vsaj 3 začetne 2-urne infuzije zdravila Remicade (uvajalna faza zdravljenja) in so trenutno na vzdrževalnem zdravljenju, lahko razmislite o skrajšanju naslednjih infuzij, vendar ne na manj kot 1 uro.
Significant improvements from baseline were demonstrated in DLQI (p < 0.001) and the physical and mental component scores of the SF 36 (p < 0.001 for each component comparison). 
Pri oceni po DLQI (p < 0,001) so dokazali bistveno izboljšanje glede na začetne vrednosti, pa tudi glede ocen telesne in duševne komponente po SF 36 (p < 0,001 za primerjavo vsake komponente).
Of these 108 patients, 27 were treated with the recommended dosage of infliximab 5 mg/kg. 
27 od teh 108 bolnikov so zdravili s priporočenim odmerkom infliksimaba, 5 mg/kg.
After infliximab treatment, patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, compared with baseline. 
Po zdravljenju z infliksimabom se je pri bolnikih zmanjšala serumska koncentracija interlevkina 6 (IL-6) in C-reaktivnega proteina (CRP) in zviša nivo hemoglobina pri bolnikih z revmatoidnim artritisom, ki imajo ta nivo sicer znižan, v primerjavi z izhodiščno vrednostjo.
Upon removal from refrigerated storage, Remicade must not be returned to refrigerated storage. 
Ko zdravilo Remicade enkrat vzamete iz hladilnika, ga ne smete vrniti nazaj v hladilnik.
The efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: SPIRIT and EXPRESS. 
Učinkovitost infliksimaba so ocenjevali v dveh multicentričnih, randomiziranih, dvojno slepih študijah: SPIRIT in EXPRESS.
• Small red or purple spots caused by bleeding under the skin 
• majhne rdeče ali vijolične pike zaradi podkožnih krvavitev
Warnings and precautions Talk to your doctor before or during treatment with Remicade if you have: 
Opozorila in previdnostni ukrepi Pred ali med zdravljenjem z zdravilom Remicade se v naslednjih primerih posvetujte z zdravnikom:
In psoriatic arthritis, short term treatment with Remicade reduced the number of T-cells and blood vessels in the synovium and psoriatic skin. 
Pri psoriatičnem artritisu je kratkotrajno zdravljenje z zdravilom Remicade zmanjšalo število celic T in krvnih žil v sinovialni ovojnici in v psoriatično spremenjeni koži.
Week 10 
10. teden
Isolated cases of liver failure resulting in liver transplantation or death have occurred. 
V osamljenih primerih je prišlo do odpovedi jeter, ki je zahtevala transplantacijo jeter ali povzročila smrt.
Cases of transient visual loss occurring during or within 2 hours of Remicade infusion have been reported. 
Poročali so o primerih prehodne izgube vida, ki je nastopila med infundiranjem ali v roku 2 ur po prejemu infuzije zdravila Remicade.
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remicade therapy. 
Priporočljivo je, da se pri pediatričnih bolnikih pred uvajanjem zdravila Remicade, če je mogoče, opravijo vsa cepljenja v skladu s trenutnimi smernicami za cepljenje.
In the re-treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus < 1% (1/222) on maintenance therapy. 
V kraku za ponovno zdravljenje so imeli 4 % bolnikov (8/219) resno z infuzijo povezano reakcijo, v primerjavi z < 1 % bolnikov (1/222) na vzdrževalnem zdravljenju.
The elimination pathways for infliximab have not been characterised. 
Poti izločanja infliksimaba niso bile ugotovljene.
Secondary endpoints included the proportion of patients in clinical remission at week 4 (CDAI < 150) and clinical response over time. 
Sekundarna cilja študije sta bila odstotek bolnikov v klinični remisiji v 4. tednu (CDAI < 150) in klinični odziv po času.
The primary endpoint of the study was corticosteroid-free clinical remission at week 26, defined as patients in clinical remission (CDAI of < 150) who, for at least 3 weeks, had not taken oral systemic corticosteroids (prednisone or equivalent) or budesonide at a dose > 6 mg/day. 
Primarni končni opazovani dogodek študije je bila klinična remisija bolezni brez jemanja kortikosteroidov v 26. tednu, ki je bila opredeljena z bolniki v klinični remisiji (vrednost CDAI < 150), ki najmanj 3 tedne niso jemali peroralnih sistemskih kortikosteroidov (prednizona oziroma njemu enakovrednih kortikosteroidov) ali budezonida v odmerku > 6 mg/dan.
Infusion reactions occurred in 35% of patients with juvenile rheumatoid arthritis receiving 3 mg/kg compared with 17.5% of patients receiving 6 mg/kg. 
Z infuzijo povezane reakcije so se pojavile pri 35 % bolnikov z juvenilnim revmatoidnim artritisom, ki so prejemali odmerek 3 mg/kg, v primerjavi s 17,5 % tistih, ki so prejemali odmerek 6 mg/kg.
Remicade will generally be stored by the health professionals. 
V glavnem bodo za shranjevanje zdravila Remicade poskrbeli zdravstveni delavci.
• You should receive recommended vaccinations before starting Remicade treatment. 
• Vsa priporočena cepljenja morate prejeti pred začetkom zdravljenja z zdravilom Remicade.
In this study 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤ 35%) were treated with 3 infusions of Remicade 5 mg/kg, 10 mg/kg, or placebo over 6 weeks. 
V tej študiji je bilo 150 bolnikov s srčnim popuščanjem stopnje III do IV po NYHA (iztisni delež levega ventrikla ≤ 35 %) zdravljenih s tremi infuzijami: zdravilo Remicade v odmerkih 5 mg/kg, 10 mg/kg ali s placebom več kot 6 tednov.
Cancer and lymphoma 
Rak in limfom
Psoriasis is an inflammatory disease of the skin. 
Psoriaza (luskavica) je vnetna bolezen kože.
Of the patients who required a dose titration, 80% achieved clinical response and the majority (64%) of these required only one adjustment of 1.5 mg/kg. 
Pri večini (67 %) teh bolnikov ni bila potrebna nikakršna titracija odmerka, med tistimi, pri katerih pa je bila titracija odmerka potrebna, jih je kar 80 % doseglo klinični odziv in večina njih (64 %) je potrebovala le eno prilagoditev odmerka za 1,5 mg/kg.
In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines. 
Živa cepiva/povzročitelji okužb v terapevtske namene Pri bolnikih, ki prejemajo anti-TNF terapijo, je na voljo malo podatkov o odzivu na cepljenje z živimi cepivi ali o sekundarnem prenosu okužbe, povzročene z živimi cepivi.
In a 6-month repeated dose toxicity study in mice, using the same analogous antibody against mouse TNF, crystalline deposits were observed on the lens capsule of some of the treated male mice. 
V 6-mesečni študiji toksičnosti pri ponavljajočih se odmerkih pri miših z uporabo istega analognega protitelesa proti mišjem TNF so opažali kopičenje kristalov na lečni kapsuli nekaterih mišjih samcev, ki so prejemali zdravilo.
This includes multiple sclerosis, Guillain-Barre syndrome, if you have fits or have been diagnosed with ‘optic neuritis'. 
To vključuje bolezni, kot so multipla skleroza, Guillain-Barréjev sindrom, če ste imeli napade krčev ali so vam diagnosticirali
Signs include joint pain or a rash on cheeks or arms that is sensitive to the sun. 
Znaki vključujejo bolečino v sklepih ali izpuščaj na licih ali rokah, ki je občutljiv na sončno svetlobo.
p-value 
p vrednost
Among patients classified as non-responders at week 2, 32% (26/81) in the placebo maintenance group and 42% (68/163) in the infliximab group achieved clinical response by week 6. 
Med bolniki, uvrščenimi v skupino brez odziva v 2. tednu, pa jih je 32 % (26/81) iz skupine za vzdrževalno zdravljenje s placebom in 42 % (68/163) iz skupine za prejemanje infliksimaba doseglo klinični odziv v 6. tednu.
In rheumatoid arthritis, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion, chemoattraction and tissue degradation. 
Pri revmatoidnem artritisu je zdravljenje z infliksimabom zmanjšalo infiltracijo vnetnih celic v vnete dele sklepov, pa tudi ekspresijo molekul, ki sodelujejo pri celični adheziji, kemotaksi in razgradnji tkiva.
At week 24, the placebo group crossed over to infliximab induction therapy (5 mg/kg) followed by infliximab maintenance therapy (5 mg/kg). 
V 24. tednu je skupina za placebo prešla na uvodno terapijo z infliksimabom (5 mg/kg), potem pa je sledila vzdrževalna terapija z infliksimabom (5 mg/kg).
• A statement that the brand name and batch number should be recorded 
• Navedba glede potrebnega beleženja imena ter številke serije zdravila.
In ASSERT, improvement in signs and symptoms was observed as early as week 2. 
V študiji ASSERT so že v 2. tednu opazili izboljšanje znakov in simptomov bolezni.
• It is important that you tell your baby's doctors and other healthcare professionals about your Remicade use before your baby is given any vaccine. 
• Pomembno je, da zdravniku vašega dojenčka in drugim zdravstvenim delavcem poveste, da ste prejemali zdravilo Remicade, še preden dojenček dobi katero koli cepivo.
• Talk to your doctor if you recently have had or are due to have a vaccine. 
• Obvestite zdravnika, če ste bili pred kratkim cepljeni ali boste cepljeni.
Patients with fistulising Crohn's disease with acute suppurative fistulas must not initiate Remicade therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3). 
Pri bolnikih s fistulirajočo Crohnovo boleznijo z akutnimi gnojnimi fistulami ne smete uvesti terapije z zdravilom Remicade, dokler ne izključite možnosti, da obstaja nekje vir okužbe, na primer absces (glejte poglavje 4.3).
Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with 13% of placebo-treated patients (p = 0.001). 
Dodatno so pri 55 % bolnikov zdravljenih z infliksimabom dosegli zapiranje vseh fistul, v primerjavi s 13 % bolnikov, ki so prejemali placebo (p = 0,001).
Can be stored at room temperature (up to 25 °C) for a single period up to 6 months, but not exceeding the original expiry date. 
Lahko se shranjuje pri sobni temperaturi (do 25 °C) za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
Abnormal skin openings 
Nenormalne odprtine na koži